| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8314117 | PFIZER | CGRP receptor antagonists |
Mar, 2030
(5 years from now) | |
| US8759372 | PFIZER | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | PFIZER | Rimegepant for CGRP related disorders |
Mar, 2039
(14 years from now) | |
Nurtec Odt is owned by Pfizer.
Nurtec Odt contains Rimegepant Sulfate.
Nurtec Odt has a total of 3 drug patents out of which 0 drug patents have expired.
Nurtec Odt was authorised for market use on 27 February, 2020.
Nurtec Odt is available in tablet, orally disintegrating;oral dosage forms.
Nurtec Odt can be used as preventive treatment of episodic migraine in adults.
Drug patent challenges can be filed against Nurtec Odt from 28 February, 2024.
The generics of Nurtec Odt are possible to be released after 25 March, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
| New Indication(I-865) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT family patents
